The use of oral human immunodeficiency virus pre-exposure prophylaxis in pregnant and lactating women in sub-Saharan Africa:considerations,barriers,and recommendations  

作　　者：Enos Moyo Grant Murewanhema Perseverance Moyo Tafadzwa Dzinamarira Andrew Ross 

机构地区：[1]School of Nursing&Public Health,College of Health Sciences,University of Kwa-Zulu Natal,Durban,South Africa [2]Faculty of Medicine and Health Sciences,University of Zimbabwe,Harare,Zimbabwe [3]Medical Centre Oshakati,Oshakati,Namibia [4]School of Health Systems and Public Health,University of Pretoria,Pretoria,South Africa

出　　处：《Global Health Journal》2024年第2期41-45,共5页全球健康杂志（英文）

摘　　要：In sub-Saharan Africa(SSA),63%of new human immunodeficiency virus(HIV)infections in 2021 were among women,particularly adolescent girls,and young women.There is a high incidence of HIV among pregnant and lactating women(PLW)in SSA.It is estimated that the risk of HIV-acquisition during pregnancy and the postpartum period more than doubles.In this article,we discuss the safety and effectiveness of drugs used for oral HIV pre-exposure prophylaxis(PrEP),considerations for initiating PrEP in PLW,the barriers to initiating and adhering to PrEP among them and suggest recommendations to address these barriers.Tenofovir/emtricitabine,the most widely used combination in SSA,is safe,clinically effective,and cost-effective among PLW.Any PLW who requests PrEP and has no medical contraindications should receive it.PrEP users who are pregnant or lactating may experience barriers to starting and adhering for a variety of reasons,including personal,pill-related,and healthcare facility-related issues.To address the barriers,we recommend an increased provision of information on PrEP to the women and the communities,increasing and/or facilitating access to PrEP among the PLW,and developing strategies to increase adherence.

关 键 词：Pre-exposure prophylaxis PREGNANCY LACTATION SAFETY Barriers RECOMMENDATIONS 

分 类 号：R512.91[医药卫生—内科学]